OncoVista Innovative Therapies

OncoVista Innovative Therapies

OncoVista Innovative Therapies is a biopharmaceutical company developing targeted anticancer therapies founded in 2004.

OncoVista Innovative Therapies, Inc. is a biopharmaceutical company that was incorporated on January 8, 1999. The company is engaged in developing and commercializing cancer therapies through the development of proprietary products as well as the acquisition of rights to technologies and drugs from others. OncoVista's product pipeline consists of advance (Phase 2) and early (Phase 1) clinical-stage compounds, late pre-clinical drug candidates and early pre-clinical leads.

The Company's therapeutic strategy is based on targeting the patient's tumors using tumor-associated biomarkers. Their products include: Cordycepin (OVI-123) and L-Nucleoside Conjugates (OVI-117). Cordycepin was OncoVista's first clinical-stage development compound. It depends upon the presence of a DNA polymerase, known as terminal deoxynucleotidyl transferase (TdT), for it's therapeutic activity.

The L-nucleoside conjugate technology works by selectively targeting certain cancer cell characteristics. This makes cancer cells vulnerable to the actions of the drug, but leaves healthy cells unaffected. OVI-117 is a thymidylate synthase (TS) inhibitor with pharmacological properties, which results in a retention of efficacy and a reduction of toxicity. It has shown tumor growth inhibitory activity in human colon, breast, and prostate tumors growing in animal models.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Alexander Weis

CEO

Tamas Bakos

Principal Research Scientist and Project Leader

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.